Can Fite Bio (CANF) AI Stock Analysis

4 Followers

Can Fite Bio

(TASE:CANF)

Select Model

Rating:38Underperform

Price Target:ILA 254.00▼(-6.07% Downside)

Action:reiterated

Date:09/14/26

The low overall score is primarily driven by weak financial performance due to minimal revenue and high cash burn, compounded by bearish technical indicators showing a strong downtrend.

Positive Factors

Low leverageVery low debt reduces near-term interest and refinancing pressure, giving the company more flexibility while it develops its clinical pipeline. This balance-sheet feature cannot offset operating losses, but it limits the financial burden associated with leverage over the next several quarters.

Negative Factors

Minimal and declining revenueThe company has not established a meaningful or growing revenue base, and the longer-term decline indicates limited commercial traction so far. This leaves future funding and value creation highly dependent on clinical progress, licensing, or other transactions rather than recurring product sales.

Can Fite Bio (CANF) vs. iShares MSCI Israel ETF (EIS)

Market Cap: ILS 11.59M
Dividend Yield: ―
Average Volume (3M): 19.29K
Price to Earnings (P/E): -0.2
Beta (1Y): -0.47
Revenue Growth: ―
EPS Growth: ―
Country: Israel
Employees: 5
Sector: General
Sector Strength: 55
Industry: Biotechnology

Can Fite Bio Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver...

How the Company Makes Money

As a clinical-stage biotech, Can-Fite has not consistently generated recurring product revenue from marketed drugs. The company’s primary sources of cash have typically been (1) external financing (e.g., public offerings or other capital raises) and...

Can Fite Bio Financial Statement Overview

Summary

Minimal TTM revenue of $405,000 and large net losses of $9.55 million lead to low income statement and cash flow scores, while the balance sheet score benefits from minimal debt of $49,000.

Income Statement

20Very Negative

Balance Sheet

52Neutral

Cash Flow

23Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	405.00K	438.40K	674.00K	743.00K	810.00K	853.00K
Gross Profit	405.00K	412.42K	674.00K	743.00K	810.00K	853.00K
EBITDA	-9.73M	-10.74M	-8.12M	-8.18M	-10.08M	-12.83M
Net Income	-9.55M	-10.64M	-7.88M	-7.63M	-10.17M	-12.60M
Balance Sheet
Total Assets	8.05M	9.52M	9.12M	9.99M	9.28M	20.25M
Cash, Cash Equivalents and Short-Term Investments	7.04M	8.54M	7.89M	8.92M	7.98M	19.14M
Total Debt	49.00K	71.01K	104.00K	40.00K	62.00K	124.00K
Total Liabilities	3.20M	3.92M	3.68M	3.75M	4.81M	5.87M
Stockholders Equity	4.86M	5.59M	5.44M	6.24M	4.47M	14.38M
Cash Flow
Free Cash Flow	-9.51M	-9.69M	-7.64M	-8.44M	-10.81M	-9.87M
Operating Cash Flow	-9.51M	-9.69M	-7.64M	-8.44M	-10.80M	-9.86M
Investing Cash Flow	-4.00M	-2,164	1.50M	498.00K	9.50M	-14.51M
Financing Cash Flow	10.04M	10.44M	6.71M	9.14M	0	20.46M

Can Fite Bio Technical Analysis

Technical Analysis SentimentNegative

Last Price270.40

Price Trends

50DMA366.01Negative

100DMA431.27Negative

200DMA510.84Negative

Market Momentum

MACD-25.62Negative

RSI25.70Positive

STOCH19.66Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 270.40 is below the 20-day moving average (MA) of 297.06, below the 50-day MA of 366.01, and below the 200-day MA of 510.84, indicating a bearish trend. The MACD of -25.62 indicates Negative momentum. The RSI at 25.70 is Positive, neither overbought nor oversold. The STOCH value of 19.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.

Can Fite Bio Risk Analysis

Can Fite Bio disclosed 68 risk factors in its most recent earnings report. Can Fite Bio reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences.Q4, 2023

Can Fite Bio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IL:CANF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IL:BLRX	41Neutral	ILS 29.87M	-1.02	―	―	-93.07%	62.25%
IL:CANF	38Underperform	ILS 16.69M	-0.25	―	―	―	―

* General Sector Average

Performance Comparison

IL:CANF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IL:CANF	Can-Fite BioPharma Ltd.	270.40	269.40	26940.00%
IL:HDST.M	HBL- Hadasit Bio-Holdings Ltd.	60.00	16.10	36.67%
IL:XTLB	XTL Biopharmaceuticals Ltd.	1.40	-2.20	-61.11%
IL:BLRX	BioLineRX Ltd.	1.00	-0.90	-47.37%
IL:GEFR	Cannomed Medical Cannabis Industries Ltd.	76.50	-5.10	-6.25%
IL:MTLF	Matricelf Ltd.	242.00	-194.00	-44.50%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 14, 2026

Can Fite Bio AI Stock Analysis